Drug Information

Drug General Information
Drug ID
D03AND
Former ID
DNCL002421
Drug Name
RAF265
Drug Type
Small molecular drug
Indication Melanoma [ICD9: 172; ICD10:C43] Phase 2 [521813], [541017]
Company
Novartis Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C24H16F6N6O
InChI
InChI=1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34)
InChIKey
YABJJWZLRMPFSI-UHFFFAOYSA-N
PubChem Compound ID
11656518
PubChem Substance ID
16760016, 26544157, 50100093, 79191747, 87231167, 103694307, 104253490, 123051132, 123055402, 124757618, 125164422, 126661315, 126731472, 135723836, 135727478, 136348734, 136367589, 137275908, 137304097, 137304118, 143499710, 152234782, 152258150, 152344206, 160646987, 162011466, 162037791, 162202589, 163908009, 172914454, 174531387, 178102301, 180386850, 185990446, 223388540, 223685438, 224081157, 226980352, 242059961, 245765895, 248532827, 249871553, 251910728, 251971069, 252216175, 252300706, 252451617, 252615336
Target and Pathway
Target(s) Vascular endothelial growth factor receptor 2 Target Info Modulator [531962]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
VEGF signaling pathway
Focal adhesion
Proteoglycans in cancer
NetPath Pathway IL2 Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathway
Pathway Interaction Database HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
VEGF and VEGFR signaling network
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY network
Reactome Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferation
WikiPathways Focal Adhesion
Nifedipine Activity
Cardiac Progenitor Differentiation
Signaling by VEGF
Angiogenesis
References
Ref 521813ClinicalTrials.gov (NCT00304525) A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma. U.S. National Institutes of Health.
Ref 541017(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5674).
Ref 531962RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.